1057P Preliminary pharmacokinetics (PK), safety and efficacy of two dosing regimens of CS1003 (anti-PD-1) in solid tumours: 200 mg every 3-week (Q3W) and 400 mg every 6-week (Q6W) dosing. - Markman, B.; Day, D.; Park, J.J.W.; Coward, J.; Bishnoi, S.; Kotasek, D.; Eek, R.; Brown, M.P.; Lemech, C.; Kuo, J.; Prawira, A.; Strother, R.; et al. (Annals of Oncology, 2020)